Astatine-211 labeling of protein using TCP as a bi-functional linker: synthesis and preliminary evaluation in vivo and in vitro
With 2,3,5,6-tetrafluorophenyl 3-( nodo -carboranyl) propionate (TCP) as a new potential bi-functional linker, bovine serum albumin (BSA) was conjugated with 211 At, and the conjugated model protein ( 211 At-TCP-BSA) was preliminarily evaluated in vitro and in vivo by comparison with 211 At-SAB-BSA...
Saved in:
Published in | Journal of radioanalytical and nuclear chemistry Vol. 288; no. 1; pp. 71 - 77 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Dordrecht
Springer Netherlands
01.04.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | With 2,3,5,6-tetrafluorophenyl 3-(
nodo
-carboranyl) propionate (TCP) as a new potential bi-functional linker, bovine serum albumin (BSA) was conjugated with
211
At, and the conjugated model protein (
211
At-TCP-BSA) was preliminarily evaluated in vitro and in vivo by comparison with
211
At-SAB-BSA and
211
At-SAPC-BSA, which conjugated with
211
At via aryl derivatives ATE (
N
-succinimidyl-3-(tri-
n
-butylstannyl) benzoate) or SPC (
N
-succinimidyl 5-(tributylstannyl)-3-pyridinecarboxylate). The radiolabeled intermediate
211
At-TCP was coupled to BSA in yields ranging from 35 to 45% with radiochemical purity of more than 98%. The conjugated
211
At-TCP-BSA exhibited considerable stability in vitro in 0.1 mol/L PBS (pH 7.6) at room temperature (RT), similar to
211
At-SAPC-BSA and
211
At-SAB-BSA. Biodistribution of the
211
At conjugated protein was investigated in NIH strain mice by I.V injection. The results showed that
211
At-TCP-BSA was constantly stable in vivo as well as in vitro, but more stable than
211
At-SAPC-BSA and
211
At-SAB-BSA. These results implied that radioastatinated carboranes based on B–At bonds are higher stability than radioastatinated aryl derivatives based on C–At to in vivo deastatination. In other word, TCP should be a promising bi-functional linker for
211
At conjugation of proteins or antibodies. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
ISSN: | 0236-5731 1588-2780 |
DOI: | 10.1007/s10967-010-0872-2 |